Bristol-Myers Squibb Company (BRM.DE)
XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
At close: 05:35PM CEST
| Previous close | 39.33 |
| Open | 39.30 |
| Bid | 39.31 x 37000 |
| Ask | 39.38 x 43000 |
| Day's range | 38.72 - 39.60 |
| 52-week range | 36.90 - 59.70 |
| Volume | |
| Avg. volume | 5,003 |
| Market cap | 79.645B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.23 (5.69%) |
| Ex-dividend date | 05 July 2024 |
| 1y target est | N/A |
- Zacks
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- Zacks
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
- Zacks
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
© 2024 Yahoo. All rights reserved.